The MoneyTree™ Report is a quarterly study of venture capital investment activity in the United States. As a collaboration between PricewaterhouseCoopers and the National Venture Capital Association based upon data from Thomson Reuters, it is the only industry-endorsed research of its kind.
The MoneyTree™ Report is a quarterly study of venture capital investment activity in the United States. As a collaboration between PricewaterhouseCoopers and the National Venture Capital Association based upon data from Thomson Reuters, it is the only industry-endorsed research of its kind. The MoneyTree Report is the definitive source of information on emerging companies that receive financing and the venture capital firms that provide it. The study is a staple of the financial community, entrepreneurs, government policymakers and the business press worldwide.
For the most recent quarter's results including VC and company lists, as well as aggregate trend data dating back to 1995, visit our interactive MoneyTree Report site: pwcmoneytree.com
Q4 2012
Cleantech received $3.3 billion of funding in 2012, a 28 percent decline in dollars and a 23 percent decline in deal volume compared to 2011.
Q4 2012: Double digit dip
Venture capital (VC) funding in the Life Sciences sector, which includes the Biotechnology and Medical Device industries dropped 14 percent during 2012 but improved at year-end.
Q4 2012: Shifting stages
Technology continues to drive the bulk of venture capital funding despite a 12 percent year-over-year investment decrease in the fourth quarter.
With technology and innovation coming of age in many emerging countries, these fast-growing markets are important destinations for private equity. Together with our US MoneyTree™ Report, these reports will help you compare trends in various parts of the world and provide a truly global view of VC/PE investments. The global MoneyTree reports serve as a reliable source of current and recent trends in PE/VC funding for: Israel, India, Russia and China (debuting soon).